{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:01:21Z","timestamp":1789963281694,"version":"4.0.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.vhri.2026.101635","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:30:46Z","timestamp":1777595446000},"page":"101635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-Effectiveness of Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in India"],"prefix":"10.1016","volume":"57","author":[{"given":"Saba","family":"Abidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denny","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shridhar","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushama","family":"Talegaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10332","key":"10.1016\/j.vhri.2026.101635_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)02391-6","article-title":"Acute coronary syndromes","volume":"399","author":"Bergmark","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vhri.2026.101635_bib2","series-title":"Acute Coronary Syndrome. Treasure Island (FL)","author":"Singh","year":"2025"},{"key":"10.1016\/j.vhri.2026.101635_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/1179546820918897","article-title":"Clinical characteristics, management strategies, and in-hospital outcomes of acute coronary syndrome in a low socioeconomic status cohort: an observational study from Urban India","volume":"14","author":"Sidhu","year":"2020","journal-title":"Clin Med Insights Cardiol"},{"issue":"22","key":"10.1016\/j.vhri.2026.101635_bib4","first-page":"2135","article-title":"ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.vhri.2026.101635_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vhri.2026.101635_bib6","article-title":"Efficacy and safety profile of ticagrelor versus clopidogrel in percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS): a systematic review and meta-analysis","volume":"15","author":"Maqbool","year":"2023","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.vhri.2026.101635_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2005.03.073","article-title":"Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"46","author":"Beinart","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.vhri.2026.101635_bib8","doi-asserted-by":"crossref","first-page":"E438","DOI":"10.9778\/cmajo.20150056","article-title":"Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model","volume":"3","author":"Abdel-Qadir","year":"2015","journal-title":"CMAJ Open"},{"issue":"4","key":"10.1016\/j.vhri.2026.101635_bib9","first-page":"307","article-title":"Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a Spanish model-based cost-effectiveness analysis","volume":"37","author":"Davies","year":"2013","journal-title":"Farm Hosp"},{"issue":"4","key":"10.1016\/j.vhri.2026.101635_bib10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3111\/13696998.2013.768998","article-title":"Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey","volume":"16","author":"Davies","year":"2013","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.vhri.2026.101635_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCULATIONAHA.109.900704","volume":"121","author":"Mahoney","year":"2010","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.vhri.2026.101635_bib12","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.clinthera.2018.10.018","article-title":"Clopidogrel versus aspirin for the treatment of acute coronary syndrome after a 12-month dual antiplatelet therapy: a cost-effectiveness analysis from China Payer\u2019s perspective","volume":"40","author":"Zhang","year":"2018","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.vhri.2026.101635_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jacasi.2022.12.007","article-title":"Cost-effectiveness of clopidogrel vs aspirin monotherapy after percutaneous coronary intervention: results from the HOST-EXAM study","volume":"3","author":"Hwang","year":"2023","journal-title":"JACC Asia"},{"issue":"5","key":"10.1016\/j.vhri.2026.101635_bib15","first-page":"71","article-title":"Factors coupled the choice of clopidogrel, prasugrel and ticagrelor in patients undergoing percutaneous coronary intervention","volume":"1","author":"Ravindran","year":"2019","journal-title":"Eur J Med Health Sci"},{"issue":"1","key":"10.1016\/j.vhri.2026.101635_bib16","first-page":"369","article-title":"Prescription pattern and drug utilization analysis in patients with acute coronary syndrome","volume":"13","author":"Saju","year":"2020","journal-title":"Indian J Pharm Pract"},{"issue":"10","key":"10.1016\/j.vhri.2026.101635_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.47583\/ijpsrr.2024.v84i10.002","article-title":"Shareef MSU, prescribing pattern of acute coronary syndrome in A tertiary Care Hospital","volume":"84","author":"Begum","year":"2024","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"2","key":"10.1016\/j.vhri.2026.101635_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/cpt.2797","article-title":"Comparative effectiveness of ticagrelor, prasugrel, and clopidogrel for secondary prophylaxis in acute coronary syndrome: a propensity score-matched cohort study","volume":"113","author":"Kumar","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vhri.2026.101635_bib19","article-title":"Development of the Indian Reference Case for undertaking economic evaluation for health technology assessment","volume":"16","author":"Sharma","year":"2023","journal-title":"Lancet Reg Health SEast Asia"},{"issue":"3","key":"10.1016\/j.vhri.2026.101635_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jval.2021.08.014","article-title":"The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review","volume":"25","author":"Kazibwe","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2026.101635_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40945-022-00154-1","article-title":"Economic evaluation: a reader\u2019s guide to studies of cost-effectiveness","volume":"12","author":"Abbott","year":"2022","journal-title":"Arch Physiother"},{"issue":"1","key":"10.1016\/j.vhri.2026.101635_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00019053-200321010-00003","article-title":"Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies","volume":"21","author":"Zethraeus","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2026.101635_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-7547-10-8","article-title":"Applying the net-benefit framework for assessing cost-effectiveness of interventions towards universal health coverage","volume":"10","author":"Hounton","year":"2012","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"10.1016\/j.vhri.2026.101635_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"2022. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2026.101635_bib26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.5603\/KP.a2014.0106","article-title":"Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer\u2019s perspective in Poland based on the Plato trial results","volume":"72","author":"Paw\u0119ska","year":"2014","journal-title":"Kardiol Pol"},{"issue":"9","key":"10.1016\/j.vhri.2026.101635_bib27","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1007\/s12325-016-0375-9","article-title":"A cost-effectiveness analysis of clopidogrel for patients with non-ST-segment elevation acute coronary syndrome in China","volume":"33","author":"Cui","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.vhri.2026.101635_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS group. ROBIS: a new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"9038","key":"10.1016\/j.vhri.2026.101635_bib30","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vhri.2026.101635_bib31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vhri.2026.101635_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijcard.2004.08.042","article-title":"Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb\/IIIa antagonists in the UK National Health Service?","volume":"100","author":"Palmer","year":"2005","journal-title":"Int J Cardiol"},{"issue":"6867","key":"10.1016\/j.vhri.2026.101635_bib33","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1136\/bmj.305.6867.1460","article-title":"Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project)","volume":"305","author":"Sandercock","year":"1992","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vhri.2026.101635_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ipej.2020.12.002","article-title":"Sudden death and its predictors in myocardial infarction survivors in an Indian population","volume":"21","author":"Selvaraj","year":"2021","journal-title":"Indian Pacing Electrophysiol J"},{"key":"10.1016\/j.vhri.2026.101635_bib35","article-title":"Stroke incidence, mortality, subtypes in rural and urban populations in five geographic areas of India (2018-2019): results from the National Stroke Registry Programme","volume":"23","author":"Rangamani","year":"2023","journal-title":"Lancet Reg Health SEast Asia"},{"key":"10.1016\/j.vhri.2026.101635_bib37","author":"Shemilt"},{"key":"10.1016\/j.vhri.2026.101635_bib38","series-title":"EQ-5D-5L user guide","year":"2019"},{"issue":"7","key":"10.1016\/j.vhri.2026.101635_bib39","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jval.2021.11.1370","article-title":"Development of an EQ-5D value set for India using an extended design (DEVINE) study: the Indian 5-level version EQ-5D value set","volume":"25","author":"Jyani","year":"2022","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2026.101635_bib40","first-page":"122","article-title":"Out-of-pocket expenditures of myocardial infarction patients in Pondicherry, South India","volume":"7","author":"Sahanaa","year":"2023","journal-title":"Evid Based Health Policy Manag Econ"},{"issue":"5","key":"10.1016\/j.vhri.2026.101635_bib41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4103\/aian.AIAN_393_19","article-title":"Economic burden of acute stroke care in beneficiaries and non-beneficiaries under social security schemes at tertiary care hospitals of western Rajasthan","volume":"23","author":"Goswami","year":"2020","journal-title":"Ann Indian Acad Neurol"},{"issue":"45","key":"10.1016\/j.vhri.2026.101635_bib42","first-page":"4078","article-title":"Five-year quality-of-life outcomes after percutaneous coronary intervention, coronary artery bypass grafting, or medical therapy (MASS II)","volume":"39","author":"Hueb","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.vhri.2026.101635_bib43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating health state utility values for economic models","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2026.101635_bib44","first-page":"3229","article-title":"Health utility values after ischemic stroke: a systematic review and meta-analysis","volume":"32","author":"Zhou","year":"2023","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.vhri.2026.101635_bib45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12955-020-01407-y","article-title":"Health utility values associated with cardiovascular disease: a systematic review","volume":"18","author":"Betts","year":"2020","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.vhri.2026.101635_bib46","article-title":"Utility values associated with modified Rankin Scale scores","volume":"3","author":"Chaisinanunkul","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"19","key":"10.1016\/j.vhri.2026.101635_bib47","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"Cannon","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.vhri.2026.101635_bib48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations","volume":"22","author":"Sittimart","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"issue":"25","key":"10.1016\/j.vhri.2026.101635_bib49","first-page":"e344","article-title":"AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.vhri.2026.101635_bib50","first-page":"819","article-title":"Cost-effectiveness of clopidogrel in acute coronary syndromes","volume":"89","author":"Mahoney","year":"2002","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.vhri.2026.101635_bib51","first-page":"1031","article-title":"Cost-effectiveness of ticagrelor compared with clopidogrel for acute coronary syndrome: a Canadian analysis","volume":"31","author":"Sandhu","year":"2015","journal-title":"Can J Cardiol"},{"issue":"29","key":"10.1016\/j.vhri.2026.101635_bib52","first-page":"1967","article-title":"Economic evaluation of ticagrelor in acute coronary syndrome based on the Plato trial","volume":"35","author":"Lindgren","year":"2014","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.vhri.2026.101635_bib53","first-page":"909","article-title":"Cost-effectiveness of clopidogrel in cardiovascular disease: a systematic review","volume":"27","author":"Roux","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.vhri.2026.101635_bib54","first-page":"e78","article-title":"ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vhri.2026.101635_bib55","article-title":"Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India","volume":"13","author":"Nehra","year":"2023","journal-title":"Lancet Reg Health SEast Asia"},{"key":"10.1016\/j.vhri.2026.101635_bib56","article-title":"Cost-effectiveness of the first line treatment options for metastatic renal cell carcinoma in India","volume":"9","author":"Gupta","year":"2023","journal-title":"JCO Glob Oncol"},{"issue":"13","key":"10.1016\/j.vhri.2026.101635_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024296","article-title":"Health state utility values in people with stroke: a systematic review and meta-analysis","volume":"11","author":"Joundi","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.vhri.2026.101635_bib58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12955-020-01407-y","article-title":"Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review","volume":"18","author":"Betts","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.vhri.2026.101635_bib59","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.13.04018","article-title":"Health-related quality of life among Indian population: the EQ-5D population norms for India","volume":"13","author":"Jyani","year":"2023","journal-title":"J Glob Health"},{"issue":"7","key":"10.1016\/j.vhri.2026.101635_bib60","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jval.2021.11.1370","article-title":"Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set","volume":"25","author":"Jyani","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2026.101635_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1612512","article-title":"Health-related quality of life among multimorbid patients using the EQ-5D-5L value set for India","volume":"13","author":"Sahoo","year":"2025","journal-title":"Front Public Health"},{"issue":"6","key":"10.1016\/j.vhri.2026.101635_bib62","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices\u2014overview: a report of the ISPOR\u2013SMDM Modeling Good Research Practices Task Force\u20131","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.vhri.2026.101635_bib63","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","article-title":"State-transition modeling: a report of the ISPOR\u2013SMDM Modeling Good Research Practices Task Force\u20133","volume":"15","author":"Siebert","year":"2012","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2026.101635_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40273-024-01449-w","article-title":"The use of real-world data for estimating relative treatment effects in National Institute for Health and Care Excellence health technology assessment submissions: a review","volume":"43","author":"Che","year":"2025","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2026.101635_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2024.100507","article-title":"Analysis of factors associated with use of real-world data in single technology appraisals of cancer drugs by the National Institute for Health and Care Excellence","volume":"42","author":"Kang","year":"2024","journal-title":"J Cancer Policy"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:16:01Z","timestamp":1789960561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":61,"alternative-id":["S2212109926000506"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101635","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in India","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101635"}}